Upgrade to SI Premium - Free Trial

Y-mAbs Therapeutics (YMAB) PT Lowered to $25 at BMO Capital

August 12, 2024 4:08 PM
BMO Capital analyst Etzer Darout lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $25.00 (from $26.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles